These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 28975467)
1. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. Arvold ND; Shi DD; Aizer AA; Norden AD; Reardon DA; Lee EQ; Nayak L; Dunn IF; Golby AJ; Johnson MD; Claus EB; Chiocca EA; Ligon KL; Wen PY; Alexander BM J Neurooncol; 2017 Dec; 135(3):581-591. PubMed ID: 28975467 [TBL] [Abstract][Full Text] [Related]
2. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter? Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159 [TBL] [Abstract][Full Text] [Related]
3. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients. Schernberg A; Dhermain F; Ammari S; Dumont SN; Domont J; Patrikidou A; Pallud J; Dezamis É; Deutsch É; Louvel G Cancer Radiother; 2018 Feb; 22(1):9-16. PubMed ID: 29217134 [TBL] [Abstract][Full Text] [Related]
4. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment. Shi W; Blomain ES; Siglin J; Palmer JD; Dan T; Wang Y; Werner-Wasik M; Glass J; Kim L; Bar Ad V; Bhamidipati D; Evans JJ; Judy K; Farrell CJ; Andrews DW J Neurooncol; 2018 Mar; 137(1):171-177. PubMed ID: 29235052 [TBL] [Abstract][Full Text] [Related]
5. Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better. Palmer JD; Siglin J; Yamoah K; Dan T; Champ CE; Bar-Ad V; Werner-Wasik M; Evans JJ; Kim L; Glass J; Farrell C; Andrews DW; Shi W J Neurooncol; 2015 Sep; 124(2):215-21. PubMed ID: 26024653 [TBL] [Abstract][Full Text] [Related]
6. Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*. Yonezawa H; Ohno M; Igaki H; Miyakita Y; Takahashi M; Tamura Y; Shima S; Matsushita Y; Ichimura K; Narita Y Jpn J Clin Oncol; 2021 Jul; 51(7):1028-1035. PubMed ID: 33959771 [TBL] [Abstract][Full Text] [Related]
7. Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. Flieger M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; la Fougère C; Ertl L; Linn J; Herrlinger U; Belka C; Niyazi M J Neurooncol; 2014 Apr; 117(2):337-45. PubMed ID: 24504501 [TBL] [Abstract][Full Text] [Related]
8. Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes. Bovi JA; Prah MA; Retzlaff AA; Schmainda KM; Connelly JM; Rand SD; Marszalkowski CS; Mueller WM; Siker ML; Schultz CJ Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):979-986. PubMed ID: 32599030 [TBL] [Abstract][Full Text] [Related]
9. Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab. Levin VA; Chan J; Datta M; Yee JL; Jain RK J Neurooncol; 2017 Sep; 134(2):325-330. PubMed ID: 28631191 [TBL] [Abstract][Full Text] [Related]
10. Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse. Antoni D; Jastaniah Z; Haoming QC; Gaultier C; Ahle G; Couchot J; Atlani D; Schott R; Clavier JB; Srour R; Chaussemy D; Noël G Cancer Radiother; 2016 Jun; 20(4):282-91. PubMed ID: 27318555 [TBL] [Abstract][Full Text] [Related]
11. Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma. Bergman D; Modh A; Schultz L; Snyder J; Mikkelsen T; Shah M; Ryu S; Siddiqui MS; Walbert T J Neurooncol; 2020 Jun; 148(2):353-361. PubMed ID: 32444980 [TBL] [Abstract][Full Text] [Related]
12. High-dose salvage re-irradiation for recurrent/progressive adult diffuse glioma: healing or hurting? Gupta T; Maitre M; Maitre P; Goda JS; Krishnatry R; Chatterjee A; Moiyadi A; Shetty P; Epari S; Sahay A; Patil V; Jalali R Clin Transl Oncol; 2021 Jul; 23(7):1358-1367. PubMed ID: 33528810 [TBL] [Abstract][Full Text] [Related]
13. Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma. Schnell O; Thorsteinsdottir J; Fleischmann DF; Lenski M; Abenhardt W; Giese A; Tonn JC; Belka C; Kreth FW; Niyazi M J Neurooncol; 2016 Dec; 130(3):591-599. PubMed ID: 27599828 [TBL] [Abstract][Full Text] [Related]
15. Fleischmann DF; Unterrainer M; Bartenstein P; Belka C; Albert NL; Niyazi M J Neurooncol; 2017 Apr; 132(2):277-286. PubMed ID: 28102485 [TBL] [Abstract][Full Text] [Related]
16. Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients. Niyazi M; Jansen NL; Rottler M; Ganswindt U; Belka C Radiat Oncol; 2014 Dec; 9():299. PubMed ID: 25529015 [TBL] [Abstract][Full Text] [Related]
17. Comparison between Reirradiation by Stereotactic Body Radiation Therapy and Moderately Hypofractionated Radiotherapy in Combination with Temozolomide for Treatment of Recurrent High Grade Glioma. Saad E; Abdelwahed M; Moussa R; Abdulla M Asian Pac J Cancer Prev; 2024 Jul; 25(7):2499-2507. PubMed ID: 39068585 [TBL] [Abstract][Full Text] [Related]
18. Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse. Tong E; Horsley P; Wheeler H; Wong M; Venkatesha V; Chan J; Kastelan M; Back M J Neurooncol; 2024 May; 168(1):69-76. PubMed ID: 38551747 [TBL] [Abstract][Full Text] [Related]
19. Concurrent hyperthermia and re-irradiation for recurrent high-grade gliomas. Heo J; Kim SH; Oh YT; Chun M; Noh OK Neoplasma; 2017; 64(5):803-808. PubMed ID: 28592133 [TBL] [Abstract][Full Text] [Related]
20. Timing of re-irradiation in recurrent high-grade gliomas: a single institution study. Zemlin A; Märtens B; Wiese B; Merten R; Steinmann D J Neurooncol; 2018 Jul; 138(3):571-579. PubMed ID: 29520609 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]